AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16946074 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 12742491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 238
Study 12742491 — intervention group
Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 238
Study 10573546 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (VO)
Number of subjects: 24
Study 10573546 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil (RO)
Number of subjects: 24
Study 8733734 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimulus displayed on a screen for 2 s followed by an unconditioned electric shock to the right middle finger.
Number of subjects: 4
Study 8733734 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus not paired with a shock.
Number of subjects: 4
Study 1862732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 6841187 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely controlled high-dose-rate intracavitary radiotherapy (30 Gy for high-dose-rate group by 3 fractions with a once a week schedule)
Number of subjects: 249
Study 6841187 — intervention group
Group type: COMPARATOR
Intervention: Manual afterloading low-dose-rate therapy (40-60 Gy with one or two fractions)
Number of subjects: 249
Study 6841187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high-dose-rate and low-dose-rate)
Number of subjects: 249
Study 30620767 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials with new anticancer biological agents
Number of subjects: 9
Study 30620767 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials with immunotherapeutic drugs
Number of subjects: 9
Study 31676222 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (50 mg once per week)
Number of subjects: 16071
Study 31676222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16071
Study 31676222 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib
Number of subjects: 16071
Study 28687275 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (n = 113)
Number of subjects: 230
Study 28687275 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (control, n = 117)
Number of subjects: 230
Study 28687275 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula
Number of subjects: 230
Study 28687275 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula
Number of subjects: 230
Study 26564281 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (100-200mg daily)
Number of subjects: 75
Study 26564281 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (2.5-5mg daily)
Number of subjects: 75
Study 23423539 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-TENS group (STG) with one active and one placebo TENS (n = 13)
Number of subjects: 39
Study 23423539 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-TENS group (DTG) with both active TENS devices applied at the low back and cervical areas
Number of subjects: 39
Study 23423539 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 39
Study 23423539 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-TENS group (STG)
Number of subjects: 39
Study 23423539 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-TENS group (DTG)
Number of subjects: 39
Study 23423539 — intervention group
Group type: COMPARATOR
Intervention: Comparison among groups (DTG vs STG vs PG)
Number of subjects: 39
Study 22416600 — intervention group
Group type: EXPERIMENTAL
Intervention: Terumo Capiox FX05 oxygenator with integrated arterial filter
Number of subjects: 40
Study 22416600 — intervention group
Group type: COMPARATOR
Intervention: Terumo Capiox RX05 Baby oxygenator and arterial filter
Number of subjects: 40
Study 22416600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FX and RX groups
Number of subjects: 40
Study 19073905 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy deficit (DEF)
Number of subjects: 18
Study 19073905 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy balance (BAL)
Number of subjects: 18
Study 16428551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg
Number of subjects: 40
Study 16428551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15622019 — intervention group
Group type: COMPARATOR
Intervention: Dichotic listening in nondirected attention condition
Number of subjects: 46
Study 15622019 — intervention group
Group type: COMPARATOR
Intervention: Dichotic listening in directed attention conditions
Number of subjects: 46
Study 15622019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening measures related to handedness
Number of subjects: 46
Study 15622019 — intervention group
Group type: COMPARATOR
Intervention: Perceptual errors in nondirected attention condition
Number of subjects: 46
Study 11501363 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 40
Study 11501363 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 40
Study 9550532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (50% to 75% maximal O2 consumption [VO2max], 200 to 300 kcal/session) 4 d/wk for 12 weeks
Number of subjects: 37
Study 9550532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 37
Study 7931231 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg per day for 12 weeks)
Number of subjects: 10
Study 7931231 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 12 weeks)
Number of subjects: 10
Study 3146506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co-dergocrine (8.0 mg)
Number of subjects: 12
Study 3146506 — intervention group
Group type: COMPARATOR
Intervention: Intravenous co-dergocrine (0.9 mg)
Number of subjects: 12
Study 3146506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous and oral doses
Number of subjects: 12
Study 31977270 — intervention group
Group type: EXPERIMENTAL
Intervention: D-index-guided early antifungal therapy (DET)
Number of subjects: 423
Study 31977270 — intervention group
Group type: COMPARATOR
Intervention: Empiric antifungal therapy (EAT)
Number of subjects: 423
Study 31246564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum IUD counseling for Sinhalese women who speak only Sinhala
Number of subjects: 4497
Study 31246564 — intervention group
Group type: COMPARATOR
Intervention: Postpartum IUD counseling for women who speak both Sinhala and Tamil
Number of subjects: 4497
Study 31246564 — intervention group
Group type: COMPARATOR
Intervention: Postpartum IUD counseling for women who speak only Tamil
Number of subjects: 4497
Study 26630216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 or 20 mg daily
Number of subjects: 854
Study 26630216 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 or 20 mg daily
Number of subjects: 854
Study 26630216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine-Enalapril combination treatment
Number of subjects: 854
Study 26630216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 854
Study 25519464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (58.5 mg/mL)
Number of subjects: 30
Study 25519464 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (9 mg/mL)
Number of subjects: 30
Study 25519464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hypertonic and isotonic saline
Number of subjects: 30
Study 25519464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 30
Study 23563904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant VH S/D 4 s-apr (Artiss)
Number of subjects: 75
Study 23563904 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) treatment
Number of subjects: 75
Study 20674480 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% carbon dioxide inhalation
Number of subjects: 10
Study 20674480 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 10
Study 18452447 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation group intervention for caregivers
Number of subjects: 113
Study 18452447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 113
Study 16548733 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKinetic (PK) Superpulse system
Number of subjects: 105
Study 16548733 — intervention group
Group type: COMPARATOR
Intervention: Conventional transurethral resection of the prostate (TURP)
Number of subjects: 105
Study 16548733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 105
Study 12900064 — intervention group
Group type: EXPERIMENTAL
Intervention: 6h retest group
Number of subjects: 50
Study 12900064 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week retest group
Number of subjects: 50
Study 10746484 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg daily
Number of subjects: 24
Study 10746484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8770673 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical correction of VPI after normal articulation placement, N=14
Number of subjects: 29
Study 8770673 — intervention group
Group type: COMPARATOR
Intervention: Speech therapy aimed to correct CA, N=15
Number of subjects: 29
Study 1579938 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (40 mg preoperatively, 40 mg on the day of surgery, 20 mg on days 1 and 2)
Number of subjects: 332
Study 1579938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 7398988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone valerate
Number of subjects: 0
Study 7398988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide
Number of subjects: 0
Study 7398988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% hydrocortisone 17‐butyrate
Number of subjects: 0
Study 7398988 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids applied after irradiation (betamethasone and hydrocortisone)
Number of subjects: 0
Study 31417163 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase inhibitors (NAIs)
Number of subjects: 0
Study 27605365 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (SC) + Text Messaging (TM) + Adherence-focused Behavioral Therapy (ABT)
Number of subjects: 158
Study 27605365 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 158
Study 25990891 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS non-payment policy
Number of subjects: 4080000
Study 23949576 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters of PEG‐EL with 1 liter of pineapple juice (Dimes 100%)
Number of subjects: 126
Study 23949576 — intervention group
Group type: COMPARATOR
Intervention: 4 liters of PEG‐EL
Number of subjects: 126
Study 23949576 — intervention group
Group type: COMPARATOR
Intervention: 2 liters of PEG‐EL
Number of subjects: 126
Study 21193066 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide isoniazid preventive therapy (IPT) offered to all employees
Number of subjects: 0
Study 21193066 — intervention group
Group type: COMPARATOR
Intervention: Routine IPT targeted to those identified as at higher risk of TB (due to HIV infection or silicosis)
Number of subjects: 0
Study 20214205 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Albumin 100 ml every 12 hours
Number of subjects: 56
Study 20214205 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethylstarch 250 ml every 6 hours
Number of subjects: 56
Study 17975450 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (energy conservation course)
Number of subjects: 169
Study 17975450 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 169
Study 16632238 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (160 mg daily for 4 weeks)
Number of subjects: 13
Study 16632238 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 mg daily for 4 weeks)
Number of subjects: 13
Study 16632238 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide and Glibenclamide (both treatments)
Number of subjects: 13
Study 12730416 — intervention group
Group type: EXPERIMENTAL
Intervention: +ISO (soy protein with 83 mg isoflavones)
Number of subjects: 150
Study 12730416 — intervention group
Group type: COMPARATOR
Intervention: -ISO (soy protein with 3 mg isoflavones)
Number of subjects: 150
Study 9926947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated tibial components
Number of subjects: 53
Study 9926947 — intervention group
Group type: COMPARATOR
Intervention: Cemented tibial components
Number of subjects: 53
Study 7591860 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced calculating task at overload levels (above 100% workload)
Number of subjects: 41
Study 7591860 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced calculating task at various workloads
Number of subjects: 41
Study 7591860 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced calculating task
Number of subjects: 41
Study 7591860 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced calculating task over time
Number of subjects: 41
Study 7591860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oz beta 2 amplitudes and critical flicker frequency
Number of subjects: 41
Study 1689679 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical biliary bypass followed by synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in Group 1.
Number of subjects: 92
Study 1689679 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in Group 2.
Number of subjects: 92
Study 1689679 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in both groups.
Number of subjects: 92
Study 1689679 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical palliation (surgical biliary bypass) in nonresectable pancreatic carcinoma.
Number of subjects: 92
Study 6987582 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg potassium penicillin or erythromycin ethylsuccinate q.i.d.
Number of subjects: 1441
Study 6987582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 1441
Study 30653338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic diagnosis by 4 Ayurvedic experts
Number of subjects: 30
Study 30653338 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus ratings
Number of subjects: 30
Study 30653338 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-related entities
Number of subjects: 30
Study 29069153 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (30 mg) plus acetaminophen (500 mg), every 4 h, for 3 days
Number of subjects: 26
Study 29069153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride (37.5 mg) plus acetaminophen (500 mg), every 4 h, for 3 days
Number of subjects: 26
Study 25599385 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 65
Study 25599385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 65
Study 25599385 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 65
Study 25599385 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 65
Study 23334613 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 60
Study 23334613 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 21982651 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib (160 mg enteric-coated tablet daily)
Number of subjects: 13000
Study 21982651 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 13000
Study 21982651 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 13000
Study 18387273 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug
Number of subjects: 0
Study 18387273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17249526 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 400
Study 17249526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 14563749 — intervention group
Group type: EXPERIMENTAL
Intervention: Daycare place at the centre providing high quality day care
Number of subjects: 143
Study 14563749 — intervention group
Group type: COMPARATOR
Intervention: Control families using other child care
Number of subjects: 143
Study 11023932 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-J biphasic shocks
Number of subjects: 338
Study 11023932 — intervention group
Group type: COMPARATOR
Intervention: 200- to 360-J monophasic shocks
Number of subjects: 338
Study 8779124 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term steroid treatment (group L) for at least 18 months
Number of subjects: 149
Study 8779124 — intervention group
Group type: COMPARATOR
Intervention: Selective treatment (group S) reserved for symptoms or deteriorating lung function
Number of subjects: 149
Study 1501567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 4186 kJ.d‐1 (1000 kcal.d‐1) with 40% fat, 40% carbohydrate, 20% protein
Number of subjects: 36
Study 1501567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 4186 kJ.d‐1 (1000 kcal.d‐1) with 20% fat, 60% carbohydrate, 20% protein
Number of subjects: 36
Study 6859300 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence therapy
Number of subjects: 625
Study 6859300 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled drinking with behavior modification
Number of subjects: 625
Study 6859300 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic services (Control)
Number of subjects: 625
Study 31520576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 mg single oral dose)
Number of subjects: 31
Study 31520576 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (control)
Number of subjects: 31
Study 31800420 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BPTB graft
Number of subjects: 150
Study 31800420 — intervention group
Group type: COMPARATOR
Intervention: Primary repair
Number of subjects: 150
Study 31800420 — intervention group
Group type: COMPARATOR
Intervention: LAD
Number of subjects: 150
Study 31800420 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 28409743 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT-guided surveillance
Number of subjects: 564
Study 28409743 — intervention group
Group type: COMPARATOR
Intervention: Planned neck dissection (ND)
Number of subjects: 564
Study 26966829 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) in combination with counseling and jaw exercise
Number of subjects: 28
Study 26966829 — intervention group
Group type: COMPARATOR
Intervention: Counseling and exercise alone
Number of subjects: 28
Study 25134002 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg·kg body mass
Number of subjects: 8
Study 25134002 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4.5 mg·kg body mass
Number of subjects: 8
Study 25134002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 22446674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit 'Free Run' program
Number of subjects: 21
Study 22446674 — intervention group
Group type: COMPARATOR
Intervention: Treadmill brisk walking
Number of subjects: 21
Study 19139296 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal models of SCN1A mutants
Number of subjects: 0
Study 17672892 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention with trained peer supporters conducting nine group meetings over two years.
Number of subjects: 420
Study 17672892 — intervention group
Group type: COMPARATOR
Intervention: Standardised diabetes care system (Control group).
Number of subjects: 420
Study 14715864 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (10.5 mg)
Number of subjects: 10
Study 14715864 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (8 mg)
Number of subjects: 10
Study 14715864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14715864 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide and Repaglinide
Number of subjects: 10
Study 11768836 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 728
Study 11768836 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 728
Study 11768836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 728
Study 9400356 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 79
Study 9400356 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 8214179 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (90-minute weekly sessions for 10 weeks)
Number of subjects: 48
Study 8214179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no group psychotherapy)
Number of subjects: 48
Study 3304367 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 9
Study 3304367 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg three times a day
Number of subjects: 9
Study 3304367 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate 40 mg twice a day
Number of subjects: 9
Study 30003027 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Ketamine (initial bolus 1 mg/kg and continuous infusion of 0.015625 mg/kg/min with dosage reduction -10%/10 min)
Number of subjects: 17
Study 30003027 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 17
Study 27043952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (Tf-CBT)
Number of subjects: 159
Study 27043952 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 159